ClinicalTrials.gg
CompletedNCT04683653Updated Nov 18, 2026

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

A Phase 1/2 interventional study of Hypofractionated Radiation and Clinical Follow-Up and Assessments in Endometrial Cancer, sponsored by University of Chicago. Completed at 5 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Chicago · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedNow Recruiting+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Enrollment
391st of 591
35 · median 60
Started
2021
with 56 others
Phase 1/2
85 of 715
42 open now
Registered
436th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 391st largest by enrollment of the 591 interventional ones that give a count, is one of 57 that started in 2021, is one of 85 in phase 1/2, and was the 436th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

190 more — sign in →

All 195 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).

03

Conditions studied

  • Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary cervical cancer or uterine cancer of any histology
  • Age ≥ 18 years.
  • Non- disease according to the International Federation of Gynecology and Obstetrics (FIGO).
  • Must have been treated with definitive intent, including standard-of-care hysterectomy, without any gross residual disease post-operatively. Nodal dissection is not required, but if it is not performed, then diagnostic imaging to confirm absence of gross pelvic or para-aortic disease should be obtained pre- or post-operatively.
  • Recommended to undergo whole pelvic radiotherapy without concurrent chemotherapy or para-aortic radiation. Chemotherapy before or after radiotherapy is acceptable.
  • (ECOG) PS≤ 2
  • Able to provide and willingness to sign an approved consent form

Exclusion criteria

Exclusion Criteria:

  • Distant as determined clinically or radiographically based upon standard-of-care work-up for endometrial cancer.
  • Concurrent (or other) chemotherapy occurring at the time of study.
  • Gross residual disease (cancer cells that remain after attempts to remove the cancer have been made) post-operatively and/or at the time of radiation based upon pre-op or post-op imaging, intra-operative findings, and gynecologic oncologists' judgment.
  • History of small bowel obstruction, inflammatory bowel disease, irritable bowel syndrome, connective tissue disorder requiring ongoing active medical management, or prior radiation therapy directed to the pelvis.
  • Unresolved grade 2 or higher chemotherapy-associated diarrhea or abdominopelvic pain requiring medication prior to the initiation of radiation.
  • Recommendation to undergo para-aortic nodal irradiation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Hypofractionated Radiation Treatment (Dose-Finding Arm)

    All study participants in this arm will receive hypofractionated whole pelvic radiation treatment for a shortened time period of 3-5 weeks. The goal of this arm is to establish a safe and tolerable dose of shortened (hypofractionated) pelvic radiation treatment for study participants. Once a safe and tolerable dose is established for this shortened form of radiation treatment, participants who meet criteria for the second phase of this study will participate in an expansion cohort that will explore the efficacy (how effective shortened/hypofractionated radiation treatment is for treating endometrial cancer).

    Radiation: Hypofractionated Radiation

  • Experimental
    Expansion Cohort (Efficacy Arm)

    Participants in this arm will test how effective hypofractionated/shortened whole radiation treatment is ("efficacy") at the dose established in the first phase of this study by following up with their doctors to report their current health status and symptoms during clinical visits. Participants will return for routine clinical follow-up approximately 1 month following radiation, then at 3 months following radiation, then every 3 months for the next 2 years following treatment.

    Other: Clinical Follow-Up and Assessments

Interventions

  • RadiationHypofractionated Radiation

    Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.

  • OtherClinical Follow-Up and Assessments

    At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the "EPIC questionnaire") during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer.

06

What researchers measure

Primary outcomes

  1. The Maximum Tolerated Dose of Hypofractionated Whole Pelvic Radiation Treatment (Phase 1)

    The maximum tolerated dose-per-fraction regimen of whole pelvic radiation therapy that will be administered during uterine cancer treatment.

    Time frame: 3-5 weeks

  2. Change in patient-reported acute gastrointestinal side effects after completion of hypofractionated radiation (Phase 2)

    Change in quality-of-life experience on the bowel and urinary domains

    Time frame: 3-5 weeks (end of treament)

Secondary outcomes

  1. Change in patient-reported acute urinary side effects

    Determined using frequency of reported events of urinary frequency, urinary incontinence, and urinary urgency on the Patient Reported Outcomes (PRO-CTCAE)

    Time frame: 1 month post radiation

  2. Change in gastrointestinal toxicity over time

    Determined using frequency of reported events of diarrhea and proctitis on the Patient Reported Outcomes (PRO-CTCAE)

    Time frame: 1 month post radiation

  3. Overall quality of life after treatment

    Total quality of life score from the Functional Assessment of Cancer Therapy (FACT)-General questionnaire will be calculated. A higher score indicates better quality of life.

    Time frame: 2 years post treatment

  4. Financial Distress of Treatment

    Change in reported financial distress in patients as reported on the Functional Assessment of Chronic Illness Therapy- COST (FACIT-COST) questionnaire. Higher scores on scale of 0-5 indicates better financial wellbeing.

    Time frame: End of treatment

  5. Treatment Satisfaction

    We will characterize the measure of regret experienced in the study patients over time as reported on the Decision Regret Scale questionnaire. Higher scores on scale of 0-100 indicates high regret.

    Time frame: End of treatment

07

Study locations

5 sites
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Nov 2026, 69 months.

Of 80 phase 1/2 interventional studies under Endometrial Neoplasms, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 106. This study's 69 months is close to that.

Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 18, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Nov 2026, last on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 24, 2020
StartActual
Jan 15, 2021
Primary completionActual
Nov 5, 2026was Aug 2026
CompletionActual
Nov 5, 2026was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting→Completed Reason for stopping removed
changed Nov 12, 2026 · changed Nov 18, 2026
Sites
5 sites changed recruiting status (4 now recruiting, 1 now active, not recruiting)
Show 5 sites
  • Winship Cancer Institute, Emory University · Atlanta, United Statesno status→Active, not recruiting
  • University of Illinois at Chicago (UIC) · Chicago, United Statesno status→Recruiting
  • University of Chicago · Chicago, United Statesno status→Recruiting
  • MD Anderson Cancer Center · Houston, United Statesno status→Recruiting
  • Huntsman Cancer Institute · Salt Lake City, United Statesno status→Recruiting
Nov 12, 2026
Primary completion
Aug 20, 2026→Nov 5, 2026 (actual)
moved 2 times, Nov 12, 2026 – Nov 18, 2026
Study completion
Dec 20, 2026→Nov 5, 2026 (actual)
moved 2 times, Nov 12, 2026 – Nov 18, 2026
Enrollment
100 (estimated)→35 (actual)
Nov 18, 2026
Contact
Study contact now listed: added c•••@bsd.uchicago.edu · •••6870. See the current contact
Nov 12, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • University of Illinois at Chicago (UIC) · Chicago, United StatesContact added m•••@uic.edu · •••1902Contact added (no phone or email listed)
  • University of Chicago · Chicago, United StatesContact added c•••@bsd.uchicago.edu · •••8222
  • MD Anderson Cancer Center · Houston, United StatesContact added r•••@mdanderson.org · •••8466Contact added g•••@mdanderson.org · •••4594Contact added (no phone or email listed)
  • Huntsman Cancer Institute · Salt Lake City, United StatesContact added r•••@hci.utah.edu · •••0115Contact added d•••@hci.utah.edu · •••4713Contact added (no phone or email listed)
Nov 12, 2026
Show all 2 updates
  1. Nov 18, 2026
    Recruiting→Completed
    Primary completion May 20, 2027→Nov 5, 2026 (now actual)
    Study completion Dec 20, 2027→Nov 5, 2026 (now actual)
    Enrollment 100 (estimated)→35 (actual)
    + 2 other changes: contact details and site details
  2. Nov 12, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    5 sites changed recruiting status (4 now recruiting, 1 now active, not recruiting)
    Show 5 sites
    • Winship Cancer Institute, Emory University · Atlanta, United Statesno status→Active, not recruiting
    • University of Illinois at Chicago (UIC) · Chicago, United Statesno status→Recruiting
    • University of Chicago · Chicago, United Statesno status→Recruiting
    • MD Anderson Cancer Center · Houston, United Statesno status→Recruiting
    • Huntsman Cancer Institute · Salt Lake City, United Statesno status→Recruiting
    Primary completion Aug 20, 2026→May 20, 2027
    Study completion Dec 20, 2026→Dec 20, 2027
    Contact Study contact now listed: added c•••@bsd.uchicago.edu · •••6870. See the current contact
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • University of Illinois at Chicago (UIC) · Chicago, United StatesContact added m•••@uic.edu · •••1902Contact added (no phone or email listed)
    • University of Chicago · Chicago, United StatesContact added c•••@bsd.uchicago.edu · •••8222
    • MD Anderson Cancer Center · Houston, United StatesContact added r•••@mdanderson.org · •••8466Contact added g•••@mdanderson.org · •••4594Contact added (no phone or email listed)
    • Huntsman Cancer Institute · Salt Lake City, United StatesContact added r•••@hci.utah.edu · •••0115Contact added d•••@hci.utah.edu · •••4713Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04683653
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Jan 15, 2021
Primary completion
Nov 5, 2026
Completion
Nov 5, 2026
Last update
Nov 18, 2026

Study contacts

Christina Son, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion